Protecting Tomorrow’s Medicines: Securing the Future of the U.S. Pharma Supply Chain

Amid growing global demands and complexities, resilience and agility have become essential for success in today’s pharmaceutical supply chains. The COVID-19 pandemic, geopolitical tensions, and reliance on foreign manufacturing have underscored vulnerabilities in the supply of APIs—the building blocks of modern medicine. To address these challenges, reshoring API production has emerged as a pivotal strategy for safeguarding the future of the U.S. pharmaceutical industry. By bringing API manufacturing back to domestic facilities, pharmaceutical companies can reduce dependency on global supply chains, mitigate risks from disruptions, and ensure a more secure and responsive system.